Your browser doesn't support javascript.
loading
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature.
Arnaud, Laurent; Furie, Richard; Morand, Eric F; Aringer, Martin; Peschken, Christine; Desta, Barnabas; Rapsomaniki, Eleni; Hedberg, Jonatan; Knagenhjelm, Jacob; Seo, Caroline; Grünfeld Eén, Tina; Sorrentino, Alessandro; Tummala, Raj; Stirnadel-Farrant, Heide A; Ding, Bo.
Afiliação
  • Arnaud L; Department of Rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Autoimmune Diseases (RESO), INSERM UMR-S 1109, Strasbourg, France.
  • Furie R; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.
  • Morand EF; Monash University, Melbourne, Victoria, Australia.
  • Aringer M; University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany.
  • Peschken C; Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Desta B; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Rapsomaniki E; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Hedberg J; BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
  • Knagenhjelm J; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Seo C; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Grünfeld Eén T; BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
  • Sorrentino A; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Tummala R; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Stirnadel-Farrant HA; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Ding B; BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden Bo.Ding@astrazeneca.com.
Lupus Sci Med ; 10(2)2023 12 20.
Article em En | MEDLINE | ID: mdl-38123459
ABSTRACT

OBJECTIVE:

The longitudinal Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS) aims to assess SLE disease course overall and according to type I interferon 4 gene signature (IFNGS). Here, we describe SPOCS patient characteristics by IFNGS and baseline disease activity.

METHODS:

SPOCS (NCT03189875) is an international study of patients with SLE according to Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) criteria. Enrolled patients from 135 centres in 8 countries were followed biannually for ≤3 years from June 2017 to November 2022. Baseline demographics, disease characteristics, organ system involvement/damage and flares were analysed descriptively according to SLE Disease Activity Index-2000 score (SLEDAI-2K <10/≥10) and IFNGS status (high/low).

RESULTS:

The study population (n=823) was 93.2% female, with mean (SD) age 45.3 (13.9) years and 11.1 (9.2) years since diagnosis; 52.4% had baseline SLICC/ACR Damage Index score ≥1. Patients with SLEDAI-2K scores ≥10 (241 of 584, 41.3%) vs <10 were younger (mean 42.8 (13.7) vs 46.6 (14.2) years; nominal p=0.001), had shorter SLE duration (10.4 (8.6) vs 12.4 (9.6) years; nominal p=0.012) and more severe flares (12.9% vs 5.3%; nominal p=0.001). IFNGS-high patients (522 of 739, 70.6%) were younger than IFNGS-low patients at first SLE manifestation (30.0 (12.7) vs 36.8 (14.6) years; nominal p<0.001). Proportions of IFNGS-high patients differed according to race (nominal p<0.001), with higher proportions among Asian (83.3%) and black (86.5%) versus white patients (63.5%). Greater proportions of IFNGS-high versus IFNGS-low patients had haematological (12.6% vs 4.1%), immunological (74.4% vs 45.6%) or dermal (69.7% vs 62.2%) involvement.

CONCLUSIONS:

We identified key characteristics of patients with high disease activity and/or elevated type I IFN signalling, populations with SLE with high unmet needs. Baseline SLEDAI-2K ≥10 was associated with shorter disease duration and more severe flares. IFNGS-high patients were younger at diagnosis and had distinct patterns of organ involvement, compared with IFNGS-low patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Lúpus Eritematoso Sistêmico Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Lupus Sci Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Lúpus Eritematoso Sistêmico Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Lupus Sci Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França